Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial

BACKGROUND Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress. RESULTS Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group. CONCLUSIONS The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI.

Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients

Paraoxonase (PON1) gene variants have been identified as risk factors for cardiovascular disease (CVD). There are two common PON1 polymorphisms at position 55 (Leu-Met change) and 192 (Gln-Arg change) of the amino acid chain. Leucine at position 55 and arginine at position 192 have been associated with increased cardiovascular risk. The increased prevalence of CVD in renal transplant recipients can be only partly explained by the increased prevalence of conventional risk factors.

Frequency of the Q192R and L55M polymorphisms of the human serum paraoxonase gene (PON1) in ten Amazonian Amerindian tribes

Human serum paraoxonase (PON1) is an esterase associated with high density lipoproteins (HDLs) in the plasma and may confer protection against coronary artery disease. Serum PON1 levels and activity vary widely among individuals and populations of different ethnic groups, such variations appearing to be related to two coding region polymorphisms (L55M and Q192R). Several independent studies have indicated that the polymorphism at codon 192 (the R form) is a significant risk factor for cardiovascular disease in some populations, although this association has not been confirmed in other populations. Given the possible associations of these mutations with heart diseases and the fact that little or nothing is known of their prevalence in Amerindian populations, we investigated the variability of both polymorphisms in ten Amazonian Indian tribes and compared the variation found with that of other Asian populations in which both polymorphisms have been investigated. The results show that the LR haplotype is the most frequent and the MR haplotype is absent in all Amerindians and Asian populations. We also found that South America Amerindians present the highest frequency of the PON1192*R allele (considered a significant risk factor for heart diseases in some populations) of all the Amerindian and Asian populations so far studied.

Die Regulation des Enzyms Paraoxonase-2 sowie dessen Einfluss auf die Hämatopoese

In der vorliegenden Arbeit wurden durch den Einsatz von drei unabhängigen Methoden Proteine und Faktoren identifiziert, die die PON2-mRNA-Expression beeinflussen. Anhand der erhaltenen Faktoren wurden verstärkt solche ausgewählt, die eine Rolle in der Tumorbiologie spielen. Unter Verwendung verschiedener Zellmodelle wurde schließlich der Effekt dieser Faktoren auf die PON2-Expression analysiert. Die Ergebnisse dieser Arbeit zeigen, dass die PON2-Expression in K562-Zellen durch den PI3K / Akt-Signalweg, der in vielen Tumoren übermäßig aktiviert vorliegt, gesteigert wird. Auch eine Beteiligung des Wnt / β-Catenin-Signalweges kann nicht ausgeschlossen werden. Pharmakologische Inhibitoren von GSK-3β, einer Kinase die in beiden Signalwegen involviert ist, führt zu einer Steigerung der PON2-Expression durch den Transkriptionsfaktor LEF-1. Des Weiteren wurde gezeigt, dass die Familie der FoxO-Transkriptionsfaktoren an der Regulation der PON2-Expression in K562-Zellen beteiligt sind, wenn gleich es für die jeweiligen FoxO-Isoformen Unterschiede gibt.rnIm Hinblick auf die Assoziation von PON2 mit Leukämien wurde anhand eines PON2-/--Mausmodells, der Einfluss von PON2 auf die Hämatopoese untersucht. Dabei wurden signifikante Unterschiede in einigen Stammzellkompartimenten festgestellt. Ferner scheint PON2 die Entwicklung von Erythrozyten und Thrombozyten zu beeinflussen. Dies äußert sich in einer offensichtlichen Splenomegalie, zumindest bei alten weiblichen PON2-/--Mäusen.rnAbschließend wurde zur Generierung eines konditionalen PON2-Überexpressionsmausmodells erfolgreich ein Gene-Targeting-Vektor entwickelt. Durch eine gewebe-, zeit- und zellspezifische Steigerung der PON2-Expression ist es möglich, den Effekt einer PON2-Überexpression im Hinblick auf verschiedene Erkrankungen zu untersuchen.rnBisher war wenig über die Regulation des humanen PON2 bekannt. Die Ergebnisse der vorliegenden Arbeit zeigen erstmals, durch welche Signalwege und Transkriptionsfaktoren PON2 in Leukämiezellen reguliert wird. Im Hinblick auf die Rolle von PON2 in der Tumorbiologie ist es erstmals möglich, die PON2-Expression gezielt durch die Inhibition bzw. Aktivierung der PON2-regulierenden Faktoren zu beeinflussen, und damit neue Wege in der Krebstherapie zu beschreiten. rn

Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.

For three decades, mammalian paraoxonase (A-esterase, aromatic esterase, arylesterase; PON, EC 3.1.8.1) has been thought to be a cysteine esterase demonstrating structural and mechanistic homologies with the serine esterases (cholinesterases and carboxyesterases). Human, mouse, and rabbit PONs each contain only three cysteine residues, and their positions within PON have been conserved. In purified human PON, residues Cys-41 and Cys-352 form an intramolecular disulfide bond and neither could function as an active-center cysteine. Highly purified, enzymatically active PON contains a single titratable sulfhydryl group. Thus, Cys-283 is the only probable candidate for an active-center cysteine. Through site-directed mutagenesis of the human cDNA, Cys-283 was replaced with either serine (C283S) or alanine (C283A). The expressed C283 (wild-type) enzyme was inactivated by para-hydroxymercuribenzoate, but the C283S and C283A mutant enzymes were not inactivated. C283A and C283S mutant enzymes retained both paraoxonase and arylesterase activities, and the Km values for paraoxon and phenyl acetate were similar to those of the wild type. Clearly, residue Cys-283 is free in active PON, but a free sulfhydryl group is not required for either paraoxonase or arylesterase activities. Consequently, it is necessary to examine other models for the active-site structure and catalytic mechanism of PON.